Paclitaxel Injection USP 100 mg /30 mg

Paclitaxel Injection USP 100 mg /30 mg  is indicated as first-line and subsequent therapy for the treatment of advanced carcinoma of the ovary. As first-line therapy, Paclitaxel Injection, USP is indicated in combination with cisplatin. Paclitaxel Injection, USP is indicated for the adjuvant treatment of node-positive breast cancer administered sequentially to standard doxorubicin-containing combination chemotherapy.

3s corporation is Supplier,Exporter ,Wholesaler  for Paclitaxel Injection USP 100 mg /30 mg in India.

India has many manufacturers who manufacture  Paclitaxel Injection USP 100 mg /30 mg .To know more contact us.

Bone marrow suppression (primarily neutropenia) is dose-dependent and is the dose-limiting toxicity. Neutrophil nadirs occurred at a median of 11 days. Paclitaxel Injection should not be administered to patients with baseline neutrophil counts of less than 1500 cells/mm³ ( < 1000 cells/mm³ for patients with KS). Frequent monitoring of blood counts should be instituted during Paclitaxel Injection treatment.

Call  doctor at once if patient has a serious side effect such as:

• fever, chills, body aches, flu symptoms, sores in  mouth and throat;
• pale skin, feeling light-headed or short of breath, rapid heart rate, trouble concentrating;
• easy bruising, unusual bleeding (nose, mouth, vagina, or rectum), purple or red pinpoint spots under your skin;
• flushing (warmth, redness).